An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.
Valeant just made its first acquisition of the year. Let’s take a closer look at three companies -- Allergan, Actavis, and Zeltiq -- which could be threatened by the company’s inorganic growth.
Let's see what the numbers say about Abbott (ABT).
Keep an eye on Amarin, Cubist, and Abaxis -- they could make big moves during today's trading.
A confluence of factors is killing off coal plants one by one.
Written off for dead in 2009, this drug may show increased efficacy at higher doses.
The Tony Awards of utilities have been announced.
Can this utility electrify your earnings?
The utility opts for regulation over generation.
Market-lagging returns could be written in this 1-Star.